JP2002539089A5 - - Google Patents

Download PDF

Info

Publication number
JP2002539089A5
JP2002539089A5 JP2000599774A JP2000599774A JP2002539089A5 JP 2002539089 A5 JP2002539089 A5 JP 2002539089A5 JP 2000599774 A JP2000599774 A JP 2000599774A JP 2000599774 A JP2000599774 A JP 2000599774A JP 2002539089 A5 JP2002539089 A5 JP 2002539089A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
solvate
acceptable salt
compound
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000599774A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002539089A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/004274 external-priority patent/WO2000049037A1/en
Publication of JP2002539089A publication Critical patent/JP2002539089A/ja
Publication of JP2002539089A5 publication Critical patent/JP2002539089A5/ja
Pending legal-status Critical Current

Links

JP2000599774A 1999-02-19 2000-02-18 成長ホルモン分泌促進薬 Pending JP2002539089A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12081399P 1999-02-19 1999-02-19
US60/120,813 1999-02-19
PCT/US2000/004274 WO2000049037A1 (en) 1999-02-19 2000-02-18 Growth hormone secretagogues

Publications (2)

Publication Number Publication Date
JP2002539089A JP2002539089A (ja) 2002-11-19
JP2002539089A5 true JP2002539089A5 (enExample) 2007-07-05

Family

ID=22392709

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000599774A Pending JP2002539089A (ja) 1999-02-19 2000-02-18 成長ホルモン分泌促進薬

Country Status (13)

Country Link
EP (1) EP1153034B1 (enExample)
JP (1) JP2002539089A (enExample)
CN (1) CN1179972C (enExample)
AR (1) AR023369A1 (enExample)
AT (1) ATE375996T1 (enExample)
AU (1) AU765642B2 (enExample)
BR (1) BR0008321A (enExample)
CA (1) CA2362303A1 (enExample)
CO (1) CO5160260A1 (enExample)
DE (1) DE60036785D1 (enExample)
IL (1) IL144350A0 (enExample)
PE (1) PE20001468A1 (enExample)
WO (1) WO2000049037A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
EP1289526A4 (en) 2000-05-30 2005-03-16 Merck & Co Inc MELANOCORTIN RECEPTOR AGONISTS
GT200100147A (es) * 2000-07-31 2002-06-25 Derivados de imidazol
US6756385B2 (en) * 2000-07-31 2004-06-29 Pfizer Inc. Imidazole derivatives
US20040106665A1 (en) * 2000-10-13 2004-06-03 Kress Thomas Joseph Resolution process for preparation of substantially pure (r) and (s) enantiomers of 2-(4-nitroimidazolyl)-4-methodxyphenylpropionic acid and salts thereof
JP2004519463A (ja) * 2001-01-23 2004-07-02 ガドール エス アー 骨の代謝病の予防および/または治療のための組成物、その組成物の調製方法およびその使用
US7125840B2 (en) 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
AU2003220441A1 (en) 2002-04-09 2003-10-27 Eli Lilly And Company Dipeptidic growth hormone secretagogues
DK1730119T3 (da) * 2004-03-23 2008-08-11 Pfizer Prod Inc Imidazolforbindelser til behandling af neurodegenerative forstyrrelser
KR20080040010A (ko) 2005-09-22 2008-05-07 화이자 프로덕츠 인코포레이티드 신경계 질환 치료용 이미다졸 화합물
US10590087B1 (en) 2019-08-09 2020-03-17 Pfizer Inc. Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
US11884634B2 (en) 2019-08-09 2024-01-30 Pfizer Inc. Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide
PE20241348A1 (es) 2021-09-01 2024-07-03 Springworks Therapeutics Inc Sintesis de nirogacestat
US11504354B1 (en) 2021-09-08 2022-11-22 SpringWorks Therapeutics Inc.. Chlorinated tetralin compounds and pharmaceutical compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107836A (en) * 1992-12-11 1998-01-04 Merck & Co Inc Spiro piperidines and homologues, their preparation and pharmaceutical preparations containing them
RO115804B1 (ro) * 1992-12-11 2000-06-30 Merck & Co Inc Derivati de spiropiperidine, procedee de preparare si compozitii farmaceutice ale acestora
US5721250A (en) * 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
JP2001502319A (ja) * 1996-10-15 2001-02-20 藤沢薬品工業株式会社 成長ホルモンの放出を促進するベンズオキセピン誘導体
ZA987383B (en) * 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
ZA987385B (en) * 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.

Similar Documents

Publication Publication Date Title
JP2002539089A5 (enExample)
JP2001526218A5 (enExample)
JP2008514732A5 (enExample)
JP2003522724A5 (enExample)
JP2002519425A5 (enExample)
JP2003500442A5 (enExample)
JP2004509061A5 (enExample)
IL101162A0 (en) Pharmaceutical compositions for oral administration comprising an indole derivative
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
RU95122775A (ru) Способ уменьшения потерь костной ткани, способ лечения остеопороза и применение соединения
JP2003503449A5 (enExample)
JP2007507494A5 (enExample)
RU2002100058A (ru) Кристаллические производные 1-метилкарбапенема
JP2002527474A5 (ja) 躁病および双極性障害の治療のための医薬
JP2003502367A5 (enExample)
SE9904413D0 (sv) Comminuted form
JP2021520400A (ja) エダラボン医薬組成物
JP2001520994A5 (enExample)
JPH10147529A5 (enExample)
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
JPH1036365A5 (enExample)
JP2001519413A5 (enExample)
JP2002526550A5 (enExample)
JP2002522462A5 (enExample)
JP2003510255A5 (enExample)